As a critical negative regulator, CTLA-4 limits immune responses of T cells to PDAC cells under the circumstances of pancreatic cancer, which provides a potential treatment option, that is, the CTLA-4 blockade. Here, CTLA4 is linked to pancreatic neoplasm.